The second half of the abstract posted by Marlys opens the hopefull possibility that Tykerb may not only begin to work where Herceptin stops but that it may prevent one of the ways cancer cells become resistant to Herceptin.
One area that is not clear from reading this abtract is wether or not overcoming this resistance to Herceptin can be achieved after it has occured. If that were to be so it would mean that Herceptin treatment should not be stopped after the addition of Tykerb.
This article adds support to the very optimistic comments made by two oncs (involved in the preclinical & phase 2 trial of Tykerb+Herceptin) in an interview in december 2006 about the early observations on the combo efficacy.(
http://www.breastcancerupdate.com/do...8_06_Chang.mp3)